A genetic analysis of viruses infecting participants in an HIV vaccine trial indicates that the vaccine is more protective against viruses that have variations at specific sites in the viral envelope. See Letter p.417
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rolland, M. et al. Nature 490, 417–420 (2012).
Rerks-Ngarm, S. et al. N. Engl. J. Med. 361, 2209–2220 (2009).
Leavy, O. Nature Rev. Immunol. 9, 755 (2009).
Gilbert, P. B. et al. J. Infect. Dis. 203, 969–975 (2011).
Burton, D. R. et al. Science 303, 316 (2004).
Haynes, B. F. et al. N. Engl. J. Med. 366, 1275–1286 (2012).
Wu, X. et al. Science 329, 856–861 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Glidden, D. Design by trial. Nature 490, 350–351 (2012). https://doi.org/10.1038/490350a
Published:
Issue date:
DOI: https://doi.org/10.1038/490350a
